Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ranolazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ranolazine SCHEMBL1534086 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124665 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL6391141 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL1495098 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL30296819 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL124666 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL612077 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL14841986 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL230758 | 0.99 | LMNA (1.00) | CYP3A4CYP2D6TSHRNFKB1ADRB2 | |
| Ranolazine SCHEMBL3462812 | 0.99 | CYP3A4 (0.98) | CYP3A4CYP2D6TSHRNFKB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3903 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-222735822-U | Automatic switching circuit of three-phase four-wire and three-phase three-wire voltage line system for intelligent instrument | 广东雅达电子股份有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-113866725-B | Method for non-uniform intermittent sampling interference of radar signals | 吉林大学 | 2024-06-07 | — | — | CN | claimed |
| US-11910418-B2 | Electronic device and method for determining uplink operation in wireless communication system | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-02-20 | — | — | US | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3697386-B1 | LIQUID COMPOSITIONS FOR PERORAL USE COMPRISING PHOSPHATIDYLGLYCEROL DERIVATIVES AND THIXOTROPIC EXCIPIENTS FOR TREATING CARDIAC CHANNELOPATHIES CAUSED BY PHARMACOLOGICAL AGENTS | SIGNPATH PHARMA INC (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2023039857-A1 | PROCESSING METHOD AND APPARATUS FOR TEMPORARY REFERENCE SIGNAL CLUSTER, COMMUNICATION DEVICE, AND STORAGE MEDIUM | 北京小米移动软件有限公司 | 2023-03-23 | — | — | WO | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| EP-3319613-B1 | USE OF AMINE CARBOXYBORANES AS THERAPEUTIC DELIVERY OF CARBON MONOXIDE AND AS GENERAL DRUG DELIVERY SYSTEM IN THE PRESENCE OF REACTIVE OXYGEN SPECIES | UNIV NEW YORK STATE RES FOUND (US) | 2023-02-22 | — | — | EP | claimed |
| CN-114828853-A | Combination therapy for cancer | 赛立斯肿瘤学创新有限公司 | 2022-07-29 | — | — | CN | claimed |
| EP-3426250-B1 | TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG CONTRAINDICATED FOR CONCOMITANT ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR | Bow River LLC (US) | 2022-03-23 | — | — | EP | claimed |
| EP-2861254-B1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA APS (DK) | 2020-04-29 | — | — | EP | claimed |
| WO-2016046672-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DIABETES | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | claimed |
| US-20150164871-A1 | Pharmaceutical Compositions for Combination Therapy | ACESION PHARMA (DK) | 2015-06-18 | — | — | US | claimed |
| EP-2861254-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | Acesion Pharma ApS (DK) | 2015-04-22 | — | — | EP | claimed |
| EP-1505977-B1 | ADMINISTRATION OF A PARTIAL FATTY ACID OXIDATION INHIBITOR SUCH AS RANOLAZINE FOR THE TREATMENT OF DIABETES | GILEAD SCIENCES INC (US) | 2014-09-10 | — | — | EP | claimed |
| WO-2013185764-A2 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | ACESION PHARMA (DK) | 2013-12-19 | — | — | WO | claimed |
| CN-100581547-C | Ranolazine sustained release tablets | JIE YAN | 2010-01-20 | — | — | CN | claimed |
| US-4567264-A | ADRENERGIC BLOCKING AGENTS | SYNTEX (U.S.A.) INC. (US) | 1986-01-28 | — | — | US | claimed |
| US-20260147077-A1 | Methods and Apparatuses to Account for Timing Errors of a User Equipment in Positioning Measurements | TELEFONAKTIEBOLAGET LM ERICSSON (PUBL) (SE) | 2026-05-28 | — | — | US | disclosed |
| US-5472707-A | Melting and cooling, filling in liquefied form into a capsule form; mixed with excipients, croscarmellose sodium dispersant and sorbitol crystal retardant | SYNTEX (U.S.A.) INC. (US) | 1995-12-05 | — | — | US | disclosed |